Lupin receives USFDA approval for generic Potassium Chloride Oral Solution USP

Lupin announced that it has received approval for its Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%) from the United States Food and Drug Administration (FDA) to market a generic version of Genus Lifesciences, Inc.'s Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%).

Lupin's Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%) is the generic version of Genus' Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%). It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient.

 

Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%) had annual sales of approximately USD 184.95 million in the US (IQVIA MAT June 2018).

Powered by Capital Market - Live News